

# FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL  
OMB Number: 3235-0287  
Estimated average burden  
hours per response... 0.5

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or  
Section 30(h) of the Investment Company Act of 1940

<b>1. Name and Address of Reporting Person *</b>  <b>DOYLE WILLIAM F</b>  (Last) (First) (Middle)  <b>C/O NOVOCURE INC., 20 VALLEY STREAM PARKWAY, SUITE 300</b>  (Street)  <b>MALVERN, PA 19355</b>  (City) (State) (Zip)	<b>2. Issuer Name and Ticker or Trading Symbol</b>  <b>Novocure Ltd [ NVCR ]</b>	<b>5. Relationship of Reporting Person(s) to Issuer</b> (Check all applicable)  <input checked="" type="checkbox"/> Director _____ 10% Owner <input checked="" type="checkbox"/> Officer (give title below) _____ Other (specify below) <b>Executive Chairman</b>
<b>3. Date of Earliest Transaction (MM/DD/YYYY)</b>  <p align="center"><b>5/8/2018</b></p>		<b>6. Individual or Joint/Group Filing (Check Applicable Line)</b>  <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person
<b>4. If Amendment, Date Original Filed (MM/DD/YYYY)</b>		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Ordinary Shares	5/8/2018		F		28756 <u>(1)(2)</u>	D	\$28.055	940795	D	
Ordinary Shares	5/9/2018		F		28652 <u>(1)(2)</u>	D	\$28.257	912143	D	
Ordinary Shares								43000	I	WFD Ventures Fund II, L.P. <u>(3)</u>
Ordinary Shares								625954	I	WFD-GP II, LLC <u>(3)</u>

**Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)**

1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

**Explanation of Responses:**

- (1) 293,840 restricted stock units ("RSUs") vested on May 2, 2018. The issuer released one-fifth of the RSUs (58,768 RSUs) as of May 3, 2018 (previously reported on a Form 4 filed on May 4, 2018), released one-fifth of the RSUs as of May 4, 2018 and one-fifth of the RSUs as of May 7, 2018 (previously reported on a Form 4 filed on May 8, 2018), and released an additional one-fifth of the RSUs as of May 8, 2018 and one-fifth of the RSUs as of May 9, 2018. Mr. Doyle has sold sufficient RSUs to cover the tax liability. One-half of the remaining RSUs is scheduled to vest on each of May 2, 2019 and May 2, 2020, subject to Mr. Doyle's continued employment through such dates, pursuant to his Restricted Share Unit Award Notice with NovoCure Limited, dated as of May 2, 2017.
- (2) Represents the sale of shares to cover tax withholding obligations in connection with the settlement and release of fully-vested restricted stock units ("RSUs") granted by the issuer to the reporting person and reported on a Form 4 filed on May 4, 2017.
- (3) Mr. Doyle is the Managing Director of WFD Ventures LLC, the sole member of WFD-GP II LLC, which is the general partner of WFD Ventures Fund II, L.P. Mr. Doyle disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest.

**Reporting Owners**

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
<b>DOYLE WILLIAM F</b> <b>C/O NOVOCURE INC.</b> <b>20 VALLEY STREAM PARKWAY, SUITE 300</b> <b>MALVERN, PA 19355</b>	<b>X</b>		<b>Executive Chairman</b>	

**Signatures**

/s/ William F. Doyle

5/10/2018

\*\*Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.